Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Working Knowledge
Business Research for Business Leaders
  • Browse All Articles
  • Popular Articles
  • Cold Call Podcast
  • Managing the Future of Work Podcast
  • About Us
  • Book
  • Leadership
  • Marketing
  • Finance
  • Management
  • Entrepreneurship
  • All Topics...
  • Topics
    • COVID-19
    • Entrepreneurship
    • Finance
    • Gender
    • Globalization
    • Leadership
    • Management
    • Negotiation
    • Social Enterprise
    • Strategy
  • Sections
    • Book
    • Podcasts
    • HBS Case
    • In Practice
    • Lessons from the Classroom
    • Op-Ed
    • Research & Ideas
    • Research Event
    • Sharpening Your Skills
    • What Do You Think?
  • Browse All
    Private and Social Returns to R&D: Drug Development and Demographics
    22 Feb 2021Working Paper Summaries

    Private and Social Returns to R&D: Drug Development and Demographics

    by Efraim Benmelech, Janice Eberly, Dimitris Papanikolaou, and Joshua Krieger
    Research and development (R&D) by pharmaceutical firms focuses disproportionately on medical conditions afflicting the elderly. The proportion of R&D spending targeting older age groups is increasing over time. Even though these investments in R&D prolong life expectancy and improve quality of life, they have little effect on measured productivity and output growth.
    LinkedIn
    Email

    Author Abstract

    Investment in intangible capital—in particular, research and development—increased dramatically since the 1990s. However, output and measured productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in intangible investment is geared toward consumer products such as pharmaceutical drugs that are not included in measured economic output. We document that a significant fraction of total R&D spending in the U.S. economy is done by pharmaceutical firms and is geared to developing drugs for the elderly. Increased life expectancy among the elderly increases welfare, but is not reflected in estimates of total factor productivity.

    Paper Information

    • Full Working Paper Text
    • Working Paper Publication Date: January 2021
    • HBS Working Paper Number: 21-083
    • Faculty Unit(s): Entrepreneurial Management
      Trending
        • 19 Sep 2023
        • HBS Case

        How Will the Tech Titans Behind ChatGPT, Bard, and LLaMA Make Money?

        • 05 Sep 2023
        • Research & Ideas

        Failing Well: How Your ‘Intelligent Failure’ Unlocks Your Full Potential

        • 12 Sep 2023
        • Book

        Successful, But Still Feel Empty? A Happiness Scholar and Oprah Have Advice for You

        • 14 Sep 2023
        • Research & Ideas

        Working Moms Are Mostly Thriving Again. Can We Finally Achieve Gender Parity?

        • 15 Aug 2023
        • Cold Call Podcast

        Ryan Serhant: How to Manage Your Time for Happiness

    Joshua Lev Krieger
    Joshua Lev Krieger
    Høegh Family Associate Professor of Business of Administration
    Contact
    Send an email
    → More Articles
    Find Related Articles
    • Research and Development
    • Innovation and Invention
    • Health Care and Treatment
    • Pharmaceutical

    Sign up for our weekly newsletter

    Interested in improving your business? Learn about fresh research and ideas from Harvard Business School faculty.
    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    ǁ
    Campus Map
    Harvard Business School Working Knowledge
    Baker Library | Bloomberg Center
    Soldiers Field
    Boston, MA 02163
    Email: Editor-in-Chief
    →Map & Directions
    →More Contact Information
    • Make a Gift
    • Site Map
    • Jobs
    • Harvard University
    • Trademarks
    • Policies
    • Accessibility
    • Digital Accessibility
    Copyright © President & Fellows of Harvard College